DAWN - NASDAQ
Day One Biopharmaceuticals, Inc.
$21.53
+0.0000%Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/progressive low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
At a Glance
Live SnapshotDay One Biopharmaceuticals, Inc. Management Team
Ms. Lauren Merendino M.B.A.
Chief Commercial Officer
Dr. Davy Chiodin Ph.D., Pharm.D.
Chief Development Officer
Dr. Jeremy Bender M.B.A., Ph.D.
Chief Executive Officer, President & Director
Compensation
$1,195,600
Dr. Elly Barry M.D.
Chief Medical Officer
Mr. Charles N. York II, M.B.A.
Chief Operating Officer & Chief Financial Officer
Compensation
$854,200
Ms. Jaa Roberson
Chief People Officer
Mr. John Stubenrauch Ph.D.
Chief Technology Officer
Mr. Adam Dubow J.D.
General Counsel, Chief Compliance Officer & Secretary
Compensation
$692,700
Day One Biopharmaceuticals, Inc. Insider Positioning
During the last 12 months, insiders have purchased $599K and sold $864K worth of DAWN shares, resulting in $265K of net selling activity.
3 Months
0
0.00
0
0.00
+0
+$0
3-6 Months
0
0.00
36.5K
422.98K
-423K
-$423K
6-9 Months
66.7K
599.27K
28.0K
249.62K
+350K
+$350K
9-12 Months
0
0.00
28.3K
191.47K
-191K
-$191K
Top Buyers
Dable Habib J
Director
$599K
Top Sellers
Bender Jeremy
Director, Officer: Chief Executive Officer
$430K
Dubow Adam
Officer: Gen Counsel & Secretary
$142K
York Charles N Ii
Officer: Coo And Cfo
$134K
Merendino Lauren
Officer: Chief Commercial Officer
$126K
Vasconcelles Michael
Officer: Head Of Research And Dev.
$32K
Insider Activity Analysis
Net Insider Sentiment
Slightly bearish with $265K net selling. Selling modestly exceeds buying, which could be routine diversification rather than concern.
Buy/Sell Ratio
Moderately negative ratio. Selling is roughly double the buying, which may be routine or signal caution.
Insider Participation
5 insider sellers vs. 1 buyers. Widespread selling across multiple insiders may signal concerns.
SEC Filings
DAWN - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2025 N/A | April 11, 2025 | June 02, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | April 05, 2024 | May 23, 2024 | 2024 | |
DEF 14A DEF 14A 2023 N/A | April 28, 2023 | June 22, 2023 | 2023 | |
DEF 14A DEF 14A 2022 N/A | April 28, 2022 | June 21, 2022 | 2022 |
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.